The Food and Drug Administration (FDA) has approved Imuldosa ™ (ustekinumab-srlf), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases. Imuldosa, ...

Johnson & Johnson's innovative medicines division shows promise with expected revenues of $57bn by 2025. See more about JNJ ...

Johnson & Johnson (NYSE: JNJ) recently reported its Q3 results, with revenues and earnings exceeding our estimates.

J&J beat expectations this week to launch the Q3 earnings season; a study about children treated with bluebird bio’s Skysona ...

Q3 2024 Earnings Call Transcript October 15, 2024 Johnson & Johnson beats earnings expectations. Reported EPS is $2.42, ...

Third-quarter results exceeded estimates, but the company also lowered overall earnings expectations for 2024.

Stelara is one of the most successful Crohn’s therapies, generating $10.8bn last year, Lilly hopes to introduce Omvoh as its ...

The drug is approved for multiple inflammatory conditions and is expected to launch in the first half of 2025.

On Tuesday, Johnson & Johnson (NYSE: JNJ) posted better-than-expected third quarter sales and adjusted profit. Fueled by strong results, Johnson & Johnson raised its full year profit and sales ...

Biosimilar competition is expected in early January for the company’s second highest-selling drug, putting greater focus on newer products' market trajectory.

Johnson & Johnson's immunology superstar Stelara and oncology blockbuster Darzalex have long been among the company's top ...

At 52 weeks of follow-up, more patients on Eli Lilly’s monoclonal antibody Omvoh demonstrated histologic response, suggesting ...